Omnicell (NASDAQ:OMCL) Stock Price Down 9.7% – What’s Next?

Omnicell, Inc. (NASDAQ:OMCL) was down 9.7% during trading on Thursday . The company traded as low as $47.79 and last traded at $47.88. Approximately 362,584 shares traded hands during trading, a decline of 31% from the average daily volume of 524,098 shares. The stock had previously closed at $53.05.

Analysts Set New Price Targets

Several research firms recently issued reports on OMCL. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 19th. Bank of America reiterated a “neutral” rating and issued a $57.00 price target (up previously from $44.00) on shares of Omnicell in a report on Thursday. JPMorgan Chase & Co. upped their price objective on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Craig Hallum lifted their target price on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday. Finally, Barclays boosted their target price on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $49.14.

Omnicell Trading Down 9.7 %

The firm has a market capitalization of $2.20 billion, a PE ratio of -103.54, a P/E/G ratio of 43.55 and a beta of 0.83. The firm has a fifty day moving average of $43.14 and a 200 day moving average of $35.07. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The company had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. During the same period in the prior year, the company posted $0.29 EPS. The firm’s revenue for the quarter was down 7.4% on a year-over-year basis. Equities research analysts expect that Omnicell, Inc. will post 0.64 EPS for the current year.

Hedge Funds Weigh In On Omnicell

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Omnicell by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after acquiring an additional 80,312 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of Omnicell by 32.6% during the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after acquiring an additional 508,789 shares in the last quarter. Champlain Investment Partners LLC lifted its stake in Omnicell by 16.0% during the first quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock worth $51,246,000 after purchasing an additional 241,235 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Omnicell by 0.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after purchasing an additional 3,570 shares during the period. Finally, Federated Hermes Inc. increased its stake in Omnicell by 1,113.6% during the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after purchasing an additional 909,480 shares during the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.